Addex Therapeutics announces ADX71149 study readout expected in 2Q24

Addex Therapeutics (ADXN) announced that the ADX71149 Phase 2 epilepsy clinical study is progressing with Cohort 1 completed and 80% of patients recruited into Cohort 2. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024. The primary efficacy endpoint of this study is time to baseline monthly seizure count. Collaboration partner Janssen Pharmaceuticals of Johnson & Johnson (JNJ), is responsible for the clinical development of ADX71149. As previously announced on May 10, an independent Interim Review Committee, or IRC, convened by our collaboration partner recommended to continue the study following review of unblinded data from Part 1 of patient Cohort 1.